https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Tirzepatide Provides Robust Cardiovascular Protection Versus Dulaglutide in T2D, ASCVD

Tirzepatide Provides Robust Cardiovascular Protection Versus Dulaglutide in T2D, ASCVD

In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).

administrator

Related Articles